Cardiac sympathetic denervation in symptomatic and asymptomatic carriers of the E46K mutation in the α synuclein gene
Beatriz Tijero(University of the Basque Country), J.J. Zarranz(University of the Basque Country), Nerea Foncea(Hospital de Galdakao), Inés Escalza(Hospital de Galdakao), Javier Ruiz‐Martínez(Instituto de Salud Carlos III), Johanne Somme(University of the Basque Country), Juan Carlos Gómez‐Esteban(University of the Basque Country), Horacio Kaufmann(Dysautonomia Foundation), V. Ruiz-García(University of the Basque Country), Elena Lezcano(University of the Basque Country), Verónica Llorens(Hospital de Cruces), M.A. Aniel-Quiroga(Hospital de Cruces), Ana Martı́nez(Consejo Superior de Investigaciones Científicas), C.J. Fernández-González(University of the Basque Country), Koldo Berganzo(University of the Basque Country)
Cited by 41
Related Papers
The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy
|Movement Disorders|2022|788
COVID-19: Drug Targets and Potential Treatments
|Journal of Medicinal Chemistry|2020|469
First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease
|Journal of Medicinal Chemistry|2002|448
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
|Frontiers in Molecular Neuroscience|2011|348
Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation
|Medicinal Research Reviews|2002|334